The authors summarize key discoveries that aid the clinical translation of PI3Kα and PI3Kδ inhibitors, including the PI3Kα isoform-selective inhibitor alpelisib for the treatment of breast cancer, highlighting lessons learnt and future opportunities.
[Nature Reviews Drug Discovery]
7992332
{7992332:GH8QEMFY}
apa
50
1
163511
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
